Physician profile
Phillip Hash
NPI 1316143662
$12,292.50
in general payments reported to CMS, 2019-2025
24 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $1,668 · 2021: $2,167 · 2022: $2,214 · 2023: $1,674 · 2024: $1,970 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,027 · Education: $5.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,026.81 |
| Education | $5.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,968.60 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,317.97 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $1,087.37 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $915.23 | 2019-2022 | |
| Alkermes, INC. | $780.01 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $717.40 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $707.57 | 2019-2025 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $619.06 | 2019-2024 | Jornay Pm |
| Abbvie INC. | $618.54 | 2021-2025 | |
| Corium, LLC | $605.08 | 2021-2024 | Azstarys |
| Allergan, INC. | $577.96 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $454.34 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $444.62 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $392.26 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $301.15 | 2020-2025 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $300.78 | 2023-2025 | Auvelity |
| Indivior INC. | $158.21 | 2019-2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.24 | 2020-2024 | Caplyta |
| Shire North American Group INC | $71.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $62.03 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $17.21 | 2020 | |
| Collegium Pharmaceutical, INC. | $16.93 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $12.54 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Hash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.